Skip to content

OptimizeRx OPRX Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Spok Holdings logo
Spok HoldingsSPOK
Doximity logo
DoximityDOCS
GoodRx Holdings, Inc. logo
GoodRx Holdings, Inc.GDRX
PubMatic logo
PubMaticPUBM
Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
Quad Graphics logo
Quad GraphicsQUAD

Other financials

Income statement

See full
Revenue$19.8M-9.5%
Gross profit$14.9M+11.9%
Operating income$396.0K+119%
Net income-$495.0K+77.5%
EPS (diluted)-$0.03+75.0%

Balance sheet

See full
Cash & equivalents$20.2M+21.7%
Total debt$23.7M-27.7%
Total equity$129.6M+11.5%
Total assets$167.3M-0.3%

Cash flow

See full
Operating cash flow-$467.0K-112%
CapEx$21.0K-22.2%
Free cash flow-$488.0K-113%

Valuation

See full
Market cap$107.34M-54.1%
Enterprise value$110.88M-55.0%
P/E15.7×
P/S-1.2×

Profitability

See full
Gross margin70%+14.1pp
Operating margin13.2%
Net margin6.4%+3.6pp
FCF margin13.4%+4.8pp

Returns & leverage

See full
Return on equity5.6%+3.3pp
Debt / equity0.2×-0.1×
Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OptimizeRx's preferred stock, shares authorized?
OptimizeRx (OPRX) reported preferred stock, shares authorized of $10M in Q1 2026.
How has OptimizeRx's preferred stock, shares authorized changed year-over-year?
OptimizeRx's preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for OptimizeRx's preferred stock, shares authorized?
Over 5 years (2020 to 2025), OptimizeRx's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.